首页> 外文期刊>Cancer biotherapy and radiopharmaceuticals >The use of ((125)I) scintigraphic in vivo imaging in melanoma-bearing mice for a rapid prescreening of vectors to melanoma tissue.
【24h】

The use of ((125)I) scintigraphic in vivo imaging in melanoma-bearing mice for a rapid prescreening of vectors to melanoma tissue.

机译:黑色素瘤小鼠体内((125)I)闪烁显像的体内成像用于快速预筛选黑色素瘤组织的载体。

获取原文
获取原文并翻译 | 示例
           

摘要

INTRODUCTION: The use of radiolabeled molecules allows the study of in vivo biodistribution, target organs, and kinetic profile after systemic administration by 1) radioactive organ counting and 2) quantitative autoradiographic analysis of whole-body slices (WBA). However, these techniques are time- and animal consuming for several times studied. So, in vivo scintigraphic imaging should appear of interest for a first screening of compounds, as it is able to rapidly demonstrate tumoral uptake and kinetics by serial examinations in the same mice. MATERIALS AND METHODS: In this study, the tumoral distribution and kinetics of six molecules considered as potential melanoma tracers radiolabeled with (125)I were analyzed by gamma-scintigraphy comparatively to the results obtained by WBA. Tumoral uptake has been quantified and expressed by: 1) tumor-to-background ratios and 2) standardized tumoral uptake (STU) in percent injected dose per gram, with tumor weight being extrapolated from the measurement of the two diameters. RESULTS: Results from STU analysis showed good agreement (correlation coefficient = 0.92) with those of WBA, and the same classification of compounds (on the basis of their melanoma affinity) was obtained, with two compounds (of six) being rejected. CONCLUSIONS: [(125)I] scintigraphic imaging appeared as a relevant, easy-going method for a first pharmacologic selection in mice.
机译:简介:使用放射性标记的分子可以通过1)放射性器官计数和2)全身切片(WBA)的定量放射自显影分析研究全身给药后的体内生物分布,靶器官和动力学特征。然而,这些技术耗费了数倍的时间和精力。因此,体内闪烁显像成像对于化合物的首次筛选应引起人们的兴趣,因为它能够通过在同一只小鼠中进行系列检查迅速显示出肿瘤摄取和动力学。材料与方法:在这项研究中,通过γ闪烁显像法分析了被认为用(125)I放射性标记的潜在黑素瘤示踪剂的六个分子的肿瘤分布和动力学,与WBA的结果进行了比较。肿瘤吸收已被量化并表示为:1)肿瘤与背景的比率和2)以每克注射剂量的百分数表示的标准化肿瘤吸收(STU),从两个直径的测量推算出肿瘤重量。结果:STU分析的结果显示与WBA的一致性好(相关系数= 0.92),并且获得了相同的化合物分类(基于它们的黑素瘤亲和力),其中有两种化合物(共六种)被拒绝。结论:[(125)I]闪烁显像似乎是相关的,易于进行的小鼠首次药理选择方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号